Application Note: ANCCSSOLAHZ&LN

LC-MS/MS Method for the Determination of HCTZ and Losartan from Human Plasma Using SOLA CX

Joanne Jones, Kimberley Phipps, Thermo Fisher Scientific, Runcorn, Cheshire, UK

Key Words

- SPE
- SOLA CX Cartridges and Plates
- Accucore aQ
- hydrochlorothiazide (HCTZ)
- Losartan

Abstract

Thermo Scientific SOLA CX cartridges allow for faster methods, more reproducible results and requires smaller sample volumes than conventional loose-packed SPE cartridges. Coupled with a Thermo Scientific Accucore aQ column this allows the separation of losartan and HCTZ in human plasma with good peak shape and sensitivity in two minutes.

Introduction

SOLA[™] products are a revolutionary new Solid Phase Extraction (SPE) product range. This first in class SPE product range introduces next-generation, innovative technological advancements, giving unparalleled performance characteristics compared to conventional SPE, phospholipid and protein precipitation products.

This includes:

- Higher levels of reproducibility
- Higher levels of extract cleanliness
- Reduced solvent requirements
- Increased sensitivity

SOLA products have significant advantages for the analyst when processing compounds in complex matrices particularly in high throughput bioanalytical and clinical laboratories where reduced failure rate, higher analysis speed and lower sample/solvent requirements are critical.

The increased performance from SOLA products provides confidence in analytical results and lowers cost without compromising ease of use or requiring complex method development.


Accucore[™] HPLC columns use Core Enhanced Technology to facilitate fast and high efficiency separations. The 2.6µm diameter particles are not totally porous, but rather have a solid core and a porous outer layer. The optimised phase bonding creates a series of high coverage, robust phases. The polar functional group used to end-cap Accucore aQ provides an additional controlled interaction mechanism by which polar compounds can be retained and resolved making Accucore aQ ideal for the quantitative analysis of trace levels of polar analytes.

Hydrochlorothiazide (HCTZ) (Figure 1) is a thiazide diuretic which is commonly used in the treatment of fluid retention and hypertension by increasing sodium elimination from the body. HCTZ is on the market under a number of trade names and also through multiple generic manufacturers.

Losartan is an angiotensin II receptor antagonist also used for the treatment of hypertension. Losartan (Figure 2) has also demonstrated an ability to delay the



progression of kidney related diseases in people with type 2 diabetes and combined with HCTZ is used in the treatment of high blood pressure. The extraction of HCTZ and losartan from human plasma is demonstrated in this application.






Figure 1. Hydrochlorothiazide (HCTZ) Figu

Figure 2. Losartan

Experimental Details

| Consumables | Part Number |
|--|----------------|
| Fisher Scientific HPLC grade water | W/0106/17 |
| Fisher Scientific HPLC grade acetonitrile | A/0626/17 |
| Fisher Scientific Analytical grade formic acid | F/1900/PB08 |
| NSC Mass Spec Certified 2 mL clear via with blue bonded PTFE silicone cap | MSCERT4000-34W |

| Sample Handling Equipment | Part Number | |
|---|-------------|--|
| SPE Positive pressure manifold Thermo Fisher Scientific | 60104-232 | |
| Thermo Scientific Ultra-Van | CLS-229070 | |

Sample Pretreatment

Aliquot 121.4 μL of spiked plasma into a clean tube. Add 13.6 μL of standard spiking solution, and 15 μL of Internal Standard spiking solution, for blanks add methanol, mix well



| Sample Preparation - S | SOLA CX | Part Number |
|------------------------|--|-------------|
| Compound(s): | HCTZ, losartan, furosemide (IS | S) |
| Matrix: | Human plasma | |
| Cartridge type: | Thermo Scientific SOLA CX 10mg/1mL | 60109-002 |
| Conditioning stage: | 1 mL methanol, 1 mL water | |
| Application stage: | 100 μL of spiked human plasma containing internal standard | |
| Washing stage: | 200 µL water + 0.1% formic a | cid |
| Elution stage: | 200 µL acetonitrile + 3% amm | ionia |
| Additional stage: | dry down samples and recons of 80:20 (v/v) water / acetonit | |

| Separation Conditions | | Part Number |
|---------------------------|----------------------------------|--------------|
| Instrumentation: | Thermo Scientific Accela 600 | |
| Column: | Accucore aQ, 2.6µm 50 x 2.1mm | 17326-052130 |
| Mobile phase A: | water + 0.1% formic acid | |
| Mobile phase B: | acetonitrile + 0.1% formic ac | id |
| Gradient: | 20-70%B in 2 minutes | |
| Flow rate: | 0.4 mL/min | |
| Column temperature: | 40 °C | |
| Injection details: | 2.5 μL | |
| Injection wash solvent 1: | 80:20 (v/v) water / acetonitril | е |
| Injection wash solvent 2: | 100% organic | |
| | | |

MS Conditions

Instrumentation: Thermo Scientific TSQ Vantage

| lonization conditions | HESI |
|---------------------------|------------------------------------|
| Polarity | + Losartan / - HCTZ and Furozemide |
| Spray voltage (V) | 3000 |
| Vaporizer temp (°C) | 300 |
| Sheath gas pressure (Arb) | 60 |
| lon sweep pressure | 0 |
| Aux gas pressure (Arb) | 30 |
| Capillary temp (°C) | 300 |
| Declustering voltage | 0 |
| Collision pressure(mTorr) | 1.5 |
| Cycle time (s) | 0.5 |
| Q1 (FWHM) | 0.7 |
| Q3 (FWHM) | 0.7 |

Table 1. Vantage[™] conditions

| Compound | HCTZ | | Losartan | | Furozemide | |
|------------------|---------|---------|----------|---------|------------|---------|
| Parent (m/z) | 295.937 | | 423.2 | | 329 | .122 |
| Products (m/z) | 205.018 | 269.025 | 180.092 | 207.072 | 205.022 | 385.031 |
| Collision energy | 24 | 20 | 35 | 20 | 22 | 16 |
| S-lens | 98 | 98 | 91 | 91 | 104 | 104 |

Table 2. Mass-transition details

Data Processing

Software: Thermo Scientific LC QUAN

Results

Overview of Precision and Recovery

Method precision was observed to be < 6.1 % RSD for both HCTZ and losartan at both high and low QC concentrations (table 3). Recoveries were also measured at 86.4% and 65.8% for HCTZ and losartan respectively.

| | HCTZ | Losartan |
|---------------------------------|------|----------|
| % RSD @ Low QC | 3.3 | 6.1 |
| % RSD @ High QC | 1.6 | 4.3 |
| Accuracy (% Difference) Low QC | 11.3 | 7.6 |
| Accuracy (% Difference) High QC | 11.7 | -2.0 |
| % Recovery | 86.4 | 65.8 |

Table 3. Recovery and Precision of HCTZ and Losartan on SOLA CX cartridges

Hydrochlorothiazide (HCTZ)

Extracted HCTZ standards from human plasma were linear over the dynamic range between 0.5 and 500 ng/mL with an r² of 0.9974 using SOLA CX cartridges (Figure 6). QC samples were run in triplicate at both low and high concentrations of 1.5 ng/mL and 400 ng/mL. Precision for each QC level were < 3.5% RSD (Table 5). Overspikes were run in duplicate at a concentration of 400 ng/mL and used to calculate the percentage recovery level for HCTZ of 86.4% (Table 6). No carryover was observed for HCTZ (Table 7).

Losartan

Extracted losartan standards from human plasma were linear over the dynamic range between 0.5 and 500 ng/mL with an r² of 0.9956 using SOLA CX cartridges (Figure 7). QC samples were run in triplicate at low and high concentrations of 1.5 ng/mL and 400 ng/mL respectively. Precision for each QC level were < 6.5% (Table 9). Overspikes were ran in duplicate at a concentration of 400 ng/mL and used to calculate the percentage recovery level for losartan of 65.8% (Table 10). An assessment of carryover was made using the response of the compounds in the blank injection which followed the top standard. Due to carryover, two blanks were analysed after the top standard had been injected (Table 11).

| Sample | Calculated Concentration | % Diff |
|------------|--------------------------|--------|
| Std1_SOLA | 0.537 | 7.4 |
| Std2_SOLA | 1.04 | 4.3 |
| Std3_SOLA | 2.37 | -5.3 |
| Std4_SOLA | 10.1 | 0.86 |
| Std5_SOLA | 47.1 | -5.8 |
| Std6_SOLA | 91.3 | 8.7 |
| Std7_SOLA | 274 | 9.8 |
| Std8_SOLA | 488 | -2.5 |
| Std9_SOLA2 | 499 | 0.1 |

Table 4. Results for standard extraction line for HCTZ using SOLA CX cartridges

| Sample | Specified Concentration | Calculated Concentration | Mean % Diff | % RSD |
|---------------|----------------------------|-----------------------------|----------------|-------|
| QC low (n=3) | 1.500 | 1.68 | 11.3 | 3.3 |
| QC high (n=3) | 400.000 | 447 | 11.7 | 1.6 |

Table 5. Results for triplicate QC extractions at two concentrations for HCTZ using SOLA CX cartridges

| Average % RECOVERY (High QC) | 86.4 |
|------------------------------|------|
| | |

Table 6. Recovery data for HCTZ using SOLA CX cartridges

| Area response std 1 | 60 |
|--|------|
| 20% area response std 1 | 12 |
| Area response of blank after top std (9) | 0 |
| OVERALL | PASS |

Table 7. Carryover data for HCTZ

| Sample | Calculated Concentration (ng.mL) | % Diff |
|------------|----------------------------------|--------|
| Std1_SOLA | 0.596 | 19.1 |
| Std1_SOLA | 0.520 | 4.0 |
| std2_SOLA | 0.968 | -3.2 |
| Std3_SOLA | 2.3 | -8.1 |
| Std4_SOLA | 10.9 | 8.7 |
| Std5_SOLA | 23.4 | -6.2 |
| Std6_SOLA | 44.3 | -11.4 |
| Std7_SOLA | 87.3 | -12.7 |
| Std8_SOLA | 280 | 11.8 |
| Std9_SOLA | 487 | -2.5 |
| Std9_SOLA2 | 502 | 0.5 |
| | | |

Table 8. Results for standard extraction line for losartan using SOLA CX cartridges

| Sample | Specified Concentration (ng/mL) | Calculated Concentration (ng/mL) | Mean % Diff | % RSD |
|---------------|---------------------------------------|--|----------------|-------|
| QC low (n=3) | 1.500 | 1.61 | 11.3 | 7.6 |
| QC high (n=3) | 400.000 | 392 | -2.0 | 4.3 |

Table 9. Results for triplicate QC extractions at two concentrations for losartan using SOLA CX cartridges

| Average area response (QC high) | 3882365 | |
|-----------------------------------|---------|--|
| Average area response (overspike) | 5900415 | |
| % RECOVERY | 65.8 | |

Table 10. Recovery data for losartan using SOLA CX cartridges

| Area response std 1 | 4519 |
|--|------|
| 20% area response std 1 | 904 |
| Area response of blank 1 after top std (9) | 1189 |
| Area response of blank 2 after top std (9) | 0 |
| OVERALL | PASS |

Table 11. Carryover data for losartan




Figure 3. Extracted HCTZ from human plasma at 0.5 ng/mL using SOLA CX cartridges








Figure 4. Extracted losartan from human plasma at 0.5 $\rm ng/mL$ using SOLA CX cartridges












Figure 7. Linear dynamic range between 0.5 and 500 ng/mL with an r^2 of 0.9956 for losartan for extracted standards using SOLA CX cartridges

Conclusion

SOLA CX cartridges and Accucore aQ can be successfully used to extract and quantify HCTZ and losartan from human plasma quickly and simply. The advantages of SOLA cartridges in comparison to loose packed material ensures a reduction in elution solvent volume, hence reduced solvent costs and subsequently reduced drying times. In addition to this, good recoveries, accuracy, linearity and precision can also be achieved using SOLA cartridges, demonstrating the capabilities of the product. In addition to these offices, Thermo Fisher Scientific maintains a network of representative organizations throughout the world.

North America USA and Canada +1 800 332 3331

Europe France +33 (0)1 60 92 48 34 Germany +49 (0) 2423 9431 -20 or -21

United Kingdom +44 1928 534110

Asia Japan +81 3 5826 1615

China +86-21-68654588 or +86-10-84193588 800-810-5118

India +91-22-6742 9494

Thermo Fisher Scientific Australia Pty Ltd 1300 735 292 (free call demostic)

Thermo Fisher Scientific New Zealand Ltd 0800 933 966 (free call domestic)

All Other Enquiries +44 (0) 1928 534 050

Technical Support

North America 800 332 3331 Outside North America +44 (0) 1928 534 44

www.thermoscientific.com/chromatography

© 2011 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific Inc. and its subsidiaries. Specifications, terms and pricing are subject to change. Not all products are available in all countries. Please consult your local sales representative for details.

